Sexual Health For Women
Provider evaluation · Appropriate testing · Ongoing monitoring
Low sexual desire, vaginal dryness and painful intercourse are treated at T Clinics USA in Naples, Fort Myers, and Coral Springs. These are recognized medical conditions with FDA-approved treatments, and two of those approvals changed between December 2025 and February 2026. Results vary by individual.
Low sexual desire, vaginal dryness and painful intercourse are treated at T Clinics USA in Naples, Fort Myers, and Coral Springs. These are recognized medical conditions with FDA-approved treatments, and two of those approvals changed between December 2025 and February 2026. Results vary by individual.
GSM
HSDD
DEC 2025 & FEB 2026
PERSONALIZED CARE
GSM
HSDD
DEC 2025 & FEB 2026
PERSONALIZED CARE
GSM
HSDD
DEC 2025 & FEB 2026
PERSONALIZED CARE
TWO STEPS TO A FREE CONSULTATION
The signs are easy to dismiss. The cause is worth checking.
These are common experiences people bring to us. Two steps, about a minute, and a licensed provider's team takes it from there. Only a provider and lab work can determine what's behind them.
Step 1 of 2
Check off what sounds familiar
Tap every item below that applies to you. Tap it again to unselect. Check off as many as you like, or none at all.
Step 2 of 2
Fill out the booking form
Add your contact details below and a licensed provider's team will reach out to confirm your free consultation. Whatever you checked off in step 1 is included with your request.
This is general information, not a medical assessment or diagnosis. A licensed provider determines whether any condition is present and whether treatment is appropriate. Results vary by individual.
0 items checked off
TWO STEPS TO A FREE CONSULTATION
The signs are easy to dismiss. The cause is worth checking.
These are common experiences people bring to us. Two steps, about a minute, and a licensed provider's team takes it from there. Only a provider and lab work can determine what's behind them.
Step 1 of 2
Check off what sounds familiar
Tap every item below that applies to you. Tap it again to unselect. Check off as many as you like, or none at all.
Step 2 of 2
Fill out the booking form
Add your contact details below and a licensed provider's team will reach out to confirm your free consultation. Whatever you checked off in step 1 is included with your request.
This is general information, not a medical assessment or diagnosis. A licensed provider determines whether any condition is present and whether treatment is appropriate. Results vary by individual.
0 items checked off
You Were Probably Told There Was Nothing To Be Done
This is a dedicated service line at T Clinics USA, with personalized evaluation and ongoing care coordinated virtually or through one of our Florida clinics when appropriate.
Provider-Guided Evaluation
Two FDA Decisions In Sixty Days
On December 15, 2025 the FDA approved flibanserin for hypoactive sexual desire disorder in postmenopausal women younger than 65, the first approval extending a pharmacologic option for low desire beyond premenopausal women. Two months later, in February 2026, the FDA removed the boxed warning from low-dose vaginal estrogen. The Menopause Society said that warning may have deterred women from a safe and effective therapy for a condition affecting most menopausal women. If you raised either of these concerns with a doctor before last winter, the advice you received was shaped by a landscape that has since changed. Whether any of it applies to you is still an individual clinical question, answered by a provider who has reviewed your history.
Two FDA Decisions In Sixty Days
On December 15, 2025 the FDA approved flibanserin for hypoactive sexual desire disorder in postmenopausal women younger than 65, the first approval extending a pharmacologic option for low desire beyond premenopausal women. Two months later, in February 2026, the FDA removed the boxed warning from low-dose vaginal estrogen. The Menopause Society said that warning may have deterred women from a safe and effective therapy for a condition affecting most menopausal women. If you raised either of these concerns with a doctor before last winter, the advice you received was shaped by a landscape that has since changed. Whether any of it applies to you is still an individual clinical question, answered by a provider who has reviewed your history.
A Recognized Diagnosis, Not A Stage Of Life
Women’s sexual health is evaluated with personalized medical oversight, with virtual and in-clinic care options available when appropriate.
2 approvals
The FDA expanded flibanserin to postmenopausal women under 65 in December 2025 and removed the boxed warning from low-dose vaginal estrogen in February 2026.
2 approvals
The FDA expanded flibanserin to postmenopausal women under 65 in December 2025 and removed the boxed warning from low-dose vaginal estrogen in February 2026.
1 in 10
Hypoactive sexual desire disorder is estimated to affect roughly 10% of women in the United States.
1 in 10
Hypoactive sexual desire disorder is estimated to affect roughly 10% of women in the United States.
Provider-guided
Care is coordinated by the same medical team, virtually or through the Naples, Fort Myers, or Coral Springs clinics depending on the patient and what the provider determines is appropriate.
Provider-guided
Care is coordinated by the same medical team, virtually or through the Naples, Fort Myers, or Coral Springs clinics depending on the patient and what the provider determines is appropriate.
How It Works
How This Is Evaluated At T Clinics
01
NAMING WHAT IS ACTUALLY HAPPENING
Physical discomfort and low desire are different problems that often appear together.
Your provider takes a full history covering vaginal, sexual and urinary symptoms in one conversation, because they share a cause and are almost always reported separately or not at all. Recurrent urinary tract infections after menopause are frequently part of the same picture. Pain during intercourse also suppresses desire on its own, so establishing which came first changes what gets treated.
01
NAMING WHAT IS ACTUALLY HAPPENING
Physical discomfort and low desire are different problems that often appear together.
Your provider takes a full history covering vaginal, sexual and urinary symptoms in one conversation, because they share a cause and are almost always reported separately or not at all. Recurrent urinary tract infections after menopause are frequently part of the same picture. Pain during intercourse also suppresses desire on its own, so establishing which came first changes what gets treated.
02
LOCAL VAGINAL ESTROGEN & GSM
The February 2026 labeling change removed the warning that kept many women away from this.
Local vaginal estrogen acts on the tissue rather than circulating the way oral or transdermal hormone therapy does. Genitourinary syndrome of menopause is progressive rather than self-resolving, which is why it is worth treating rather than waiting out. Whether it is appropriate for you depends on your history, and your provider reviews that in person. If you were advised against it years ago on the basis of the boxed warning, that labeling has since been revised.
02
LOCAL VAGINAL ESTROGEN & GSM
The February 2026 labeling change removed the warning that kept many women away from this.
Local vaginal estrogen acts on the tissue rather than circulating the way oral or transdermal hormone therapy does. Genitourinary syndrome of menopause is progressive rather than self-resolving, which is why it is worth treating rather than waiting out. Whether it is appropriate for you depends on your history, and your provider reviews that in person. If you were advised against it years ago on the basis of the boxed warning, that labeling has since been revised.
03
OPTIONS FOR LOW DESIRE
Low desire that causes distress is treatable. Options include hormone therapy, vaginal applications, testosterone, and peptides such as PT-141. Which one fits depends on an evaluation.
Hypoactive sexual desire disorder has two FDA-approved medications. Flibanserin is taken daily and was approved in December 2025 for postmenopausal women under 65, having previously been limited to premenopausal women. Bremelanotide is approved for premenopausal women and used as needed. Neither is right for everyone, and thyroid function, sleep, medications including antidepressants, and hormonal status all get evaluated first, because a treatable cause elsewhere changes the answer.
03
OPTIONS FOR LOW DESIRE
Low desire that causes distress is treatable. Options include hormone therapy, vaginal applications, testosterone, and peptides such as PT-141. Which one fits depends on an evaluation.
Hypoactive sexual desire disorder has two FDA-approved medications. Flibanserin is taken daily and was approved in December 2025 for postmenopausal women under 65, having previously been limited to premenopausal women. Bremelanotide is approved for premenopausal women and used as needed. Neither is right for everyone, and thyroid function, sleep, medications including antidepressants, and hormonal status all get evaluated first, because a treatable cause elsewhere changes the answer.
You have questions, we have answers.
What is genitourinary syndrome of menopause?
What is genitourinary syndrome of menopause?
Is vaginal estrogen safe?
Is vaginal estrogen safe?
Is there a treatment for low sex drive in women?
Is there a treatment for low sex drive in women?
I am postmenopausal. Are there any approved options for me?
I am postmenopausal. Are there any approved options for me?
Why do I keep getting UTIs since menopause?
Why do I keep getting UTIs since menopause?
Could my low desire be caused by something else?
Could my low desire be caused by something else?
See What Fits Your Goals